NFLX filed 4 on 2026-10-02

10 SOURCES CONFIRMED · FIRST SEEN 2026-10-02 00:00 UTC

KINDSEC Filing

DIRECTION■ Unclear/unknown

SOURCES10

ENTITIES1

STORY SIZESTANDALONE

FIRST SEEN2026-10-02 00:00 UTC

LAST UPDATE2026-10-02 00:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A Form 4 discloses an insider transaction but the filing text gives no share count, price, or buy/sell direction, so no signal can be read.

Routine insider filing, direction undisclosed

CATALYST TO WATCH

Full Form 4 details on buy or sell

MAIN RISK

Could reflect insider selling once disclosed

FULL DISPATCH

NFLX (CIK 0001370931) filed a 4 on 2026-10-02.

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

SUBJECTNetflix · NFLX

04 RECEIPTS

THE SOURCE RECORD.

10 SOURCES CONFIRMED

№ 01secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 02secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 03secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 04secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 05secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 06secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 07secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 08secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 09secsec.gov · CONFIRMING2026-10-02 00:00 UTCOPEN RECEIPT →

№ 10secsec.gov · PRIMARY2026-10-02 00:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy — Amgen2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
New Phase 3 trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer — AstraZeneca2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer — FutureChem2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC

→INFERENCEfilings generate company commentary
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.